Grace Therapeutics (GRCE) Share-based Compensation (2019 - 2026)
Grace Therapeutics (GRCE) posted Share-based Compensation of $182000.0 for Q1 2026, up 68.52% sequentially from $108000.0 in Q4 2025, and up 40.0% YoY from $130000.0 in Q1 2025.
Grace Therapeutics (GRCE) Share-based Compensation (2019 - 2026) Analysis & Trends
Grace Therapeutics has reported Share-based Compensation for 8 years, with the latest figure at $182000.0 in Q1 2026.
- Quarterly Share-based Compensation rose 40.0% year-over-year to $182000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $798000.0 (up 9.32% YoY) and the FY2026 annual result came in at $798000.0, up 9.32% from the prior year.
- Share-based Compensation advanced to $182000.0 in Q1 2026 per GRCE's latest filing, from $108000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $1.8 million in Q1 2023 and troughed at $78000.0 in Q2 2023.
- A 5-year average of $373853.6 and a median of $238000.0 in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation jumped 410.53% in 2022, then plunged 87.34% in 2024.
- Over 5 years, Share-based Compensation stood at $443000.0 in 2022, then dropped by 26.41% to $326000.0 in 2023, then plunged by 50.92% to $160000.0 in 2024, then plunged by 32.5% to $108000.0 in 2025, then jumped by 68.52% to $182000.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $182000.0, $108000.0, and $206000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Grace Therapeutics | 37.04 Mn | 37.04 Mn | - | 214,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 214,000.00 |
| Jun 30, 2026 | 214,000.00 |
| Mar 31, 2026 | 182,000.00 |
| Mar 31, 2026 | 182,000.00 |
| Dec 31, 2025 | 108,000.00 |
| Dec 31, 2025 | 108,000.00 |
| Sep 30, 2025 | 206,000.00 |
| Sep 30, 2025 | 206,000.00 |
| Jun 30, 2025 | 302,000.00 |
| Jun 30, 2025 | 302,000.00 |
| Mar 31, 2025 | 130,000.00 |
| Mar 31, 2025 | 130,000.00 |
| Dec 31, 2024 | 160,000.00 |
| Dec 31, 2024 | 160,000.00 |
| Sep 30, 2024 | 202,000.00 |
| Sep 30, 2024 | 202,000.00 |
| Jun 30, 2024 | 238,000.00 |
| Jun 30, 2024 | 238,000.00 |
| Mar 31, 2024 | 229,000.00 |
| Mar 31, 2024 | 229,000.00 |